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Recent evidence supports ‘the neurotrophin hypothesis of depression’ in its prediction that
brain-derived neurotrophic factor (BDNF) is involved in depression. However, some key
questions remain unanswered, including whether abnormalities in BDNF persist beyond the
clinical state of depression, whether BDNF levels are related to the clinical features of
depression and whether distinct antidepressants affect BDNF levels equally. We addressed
these questions and investigated serum BDNF levels in 962 depressed patients, 700 fully
remitted persons (X6 months) and 382 healthy controls. We found serum BDNF levels to be
low in antidepressant-free depressed patients relative to controls (P=0.007) and to depressed
patients who were treated with an antidepressant (P=0.001). BDNF levels of fully remitted
persons (whether unmedicated or treated with an antidepressant) were comparable to those
of controls. Analyzing the sample of antidepressant-free depressed patients showed that
BDNF levels were unrelated to the core clinical features of depression such as its severity
or first versus a recurrent episode. The antidepressant associated upregulation of serum
BDNF in depressed patients was confined to selective serotonin reuptake inhibitors (SSRIs)
(P=0.003) and St John’s wort (P=0.03). Our results suggest that low serum levels of BDNF are
a state abnormality that is evident during depression and normalizes during remission.
Increases in serum levels of BDNF during antidepressant treatment appear to be confined
to some antidepressants and do not parallel clinical characteristics, such as the severity of
depressive symptoms.
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Introduction
Brain-derived neurotrophic factor (BDNF) is a neuro-
trophin that has been linked to the viability of
neurons in brain circuits that regulate emotion,
memory, learning, sleep and appetite.
1,2 The neuro-
trophin hypothesis of depression is based on these
functions of BDNF and postulates that depression
results from stress-induced decreases in BDNF ex-
pression and that antidepressants are efficacious
because they increase BDNF expression.
3,4 Consistent
with this hypothesis are the findings that depression
is accompanied by decreased central and peripheral
levels of BDNF,
5–7 and that antidepressants elicit
an increase in BDNF levels in animal models for
depression
8 and in depressed humans.
6,7 Together
with the latency of weeks before antidepressants
become clinically effective,
9 these observations
shaped the hypothesis that the efficacy of antidepres-
sants depend on neuroadaptive changes that are
brought about by changes in BDNF signaling.
3
Taken together, there is reason to believe that BDNF
is involved in depression and in antidepressant
action. Results inconsistent with the neurotrophin
hypothesis, however, also have been reported. There
are, for example, studies that did not detect alterna-
tions in BDNF in depressed persons or in the course
of treatment with an antidepressant.
10–12 In addition,
some questions remain unanswered so that the neuro-
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13 A major
question that largely remains to be answered is whether
low BDNF levels persist beyond the clinical state of
depression.
14,15 A second question is whether BDNF
levels are related to the clinical features of depression,
such as a first versus a recurrent episode.
16,17 Yet a third
outstanding question is whether all classes of anti-
depressants affect BDNF levels equally.
6,7
We studied, cross-sectionally, serum BDNF levels
of depressed patients, remitted depressed persons
and never depressed persons. Our efforts had three
concerns: (1) to compare serum BDNF levels of
antidepressant-free and antidepressant treated cur-
rent and fully remitted depressed patients and never
depressed persons, (2) to explore the associations
between some of the core clinical features of depres-
sion and serum BDNF levels and (3) to evaluate the
association between the use of several distinct classes
of antidepressants and serum BDNF levels.
Materials and methods
Patients and sample collection
Patients were from the Netherland Study of Depres-
sion and Anxiety (NESDA). Full details on the
rationale, objectives and protocol of NESDA are
described in a previous paper by Penninx et al.
18 In
brief, NESDA is a prospective cohort study (N=2981)
that recruited patients in mental health care, primary
care and in the general population. Included were
persons with a depressive and/or an anxiety disorder,
persons with a depressive and/or an anxiety disorder
in remission and persons without a history or current
depressive or anxiety disorders. Persons who were
diagnosed with psychotic, bipolar I or II, obsessive
compulsive or severe alcohol use disorder were not
eligible. Diagnostic and Statistical Manual of Mental
Disorders, fourth edition (DSM-IV) diagnoses
19 were
assigned on the basis of responses to the Composite
International Diagnostic Interview 2.1 lifetime ver-
sion
20 that was administered by trained interviewers.
At baseline, participants provided blood samples,
underwent a medical examination and gave written
informed consent for the study that was approved by
the Ethical Committees of the participating institutes.
Our study enrolled 2044 persons (68.6% of the
NESDA sample). On the basis of the diagnosis,
antidepressant use and the availability of BDNF data,
we created five groups: antidepressant-free depressed
patients (n=541), antidepressant-treated depressed
patients (n=421), antidepressant-free remitted de-
pressed persons (n=539), antidepressant-treated
remitted depressed persons (n=161) and healthy
persons who served as controls (n=382). Depressed
patients met the criteria for a depressive episode
within the last 6 months (n=541). The majority of
these patients had a current diagnosis of depression
(n=388), but some (n=153) had a diagnosis of
depression 1–6 months prior to baseline and did not
fulfill all criteria in the past month. Persons who were
in full remission of depression were diagnosed with
major depressive disorder (MDD) somewhere in their
lives, but had been free of depression and anxiety
during at least 6 months. Persons were included in
the control group when they had: (1) no lifetime mood
or anxiety disorders, (2) no documented family
history of depression or anxiety and (3) a low score
(p14) on the inventory of depressive symptoms.
21
Antidepressants
Data on the use of antidepressants were acquired
through drug container observation and self-report.
Use of an antidepressant was defined as intake of
minimally the daily dose as recommended by the
World Health Organization
22 during the last month
on at least 50% of the days. We coded for the use of
selective serotonin reuptake inhibitors (SSRIs), ser-
otonin-norepinephrine reuptake inhibitors, tricyclic
antidepressants, noradrenergic and specific seroto-
nergic antidepressants (NaSSAs) and St John’s wort
(Hypericum perforatum). The duration of use was
expressed in months.
Clinical features of MDD
All patients were characterized on the symptom
severity of depression using the Inventory of Depres-
sive Symptom.
21 Patient samples were further char-
acterized on having a first or a recurrent depressive
episode, the presence of comorbid anxiety, the age at
onset of depression, the recency of depression, the
chronicity of depression and on the presence of
suicide ideation. The Composite International Diag-
nostic Interview
20 served as source of information
on the presence of a first or a recurrent depressive
episode, the presence of a comorbid anxiety, age at
onset of depression (that is the age at which the first
episode occurred) and the recency of depression (that
is fulfilling criteria in the past month versus fulfilling
criteria in the past 6 months but not in the past
month). Depression was considered chronic if symp-
toms had been present X24 months during the last
5 years, which was assessed using the Life Chart
method.
23 The scale for suicide ideation
24 was used to
examine the presence (yes versus no) of suicide
ideation during the past week.
BDNF protein measurements
A measure of 50ml of blood was withdrawn into
vacuum tubes between 0730 and 0930 hours after
an overnight fast. After blood collection, serum was
separated and stored at  851C until it was assayed.
BDNF protein levels were measured using the Emax
Immuno Assay system from Promega according to the
manufacturer’s protocol (Madison, WI, USA), in one
laboratory (Maastricht University) by one technician
who was blind to the diagnoses. Undiluted serum was
acid treated as this reliably increased the detectable
BDNF in a dilution-dependent way. Greiner Bio-One
high affinity 96-well plates were used. Serum samples
were diluted 100 times, and the absorbency was read
in duplicate using a Bio-Rad (Hercules, CA, USA)
Benchmark microplate reader at 450nm. The intra-
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be within 3 and 9%, respectively. Four persons had
BDNF values that were below the reliable detection
threshold of 1.56ngml
 1. These values were set at the
lower detection limit. Positive outliers (meanþ3 s.d.,
n=6) were trimmed to the meanþ3 s.d. value. There
were no differences between persons with missing
and non-missing BDNF with regard to gender
(P=0.71), age (P=0.67) and diagnoses (P=0.33).
Covariates
Potential variance due to gender, age and educational
level was controlled for in all analyses. In addition,
we controlled for body mass index (BMI), physical
activity and smoking as these variables are associated
with BDNF
25–27 and mood.
28–30 Data on weight and
height were collected, and BMI was calculated
(weight/height
2). Information on physical activity
was gathered using the International Physical Activ-
ity Questionnaire
31 and expressed as the number of
met-minutes (that is the ratio of the amount of energy
expenditure during activity to the energy expenditure
at rest). Smoking status was dichotomized as current
versus non-smoker. Time of the morning blood with-
drawal and duration of serum storage were controlled




All computations were performed in SPSS version
17.0 (SPSS, Chicago, IL, USA). BDNF values were
controlled for basic covariates in all analyses. Effect
sizes on pairwise comparisons were presented as
Cohen’s d.
34 A two-tailed a level of 0.05 was used to
determine statistical significance.
Analysis of variance (ANOVA) was used to com-
pare BDNF levels of antidepressant-free depressed
patients and antidepressant-treated depressed pa-
tients, antidepressant-free patients and antidepres-
sant-treated persons who were in remission (X6
months) and controls. Post hoc tests between the
groups were performed following a significant
F-statistic using Tukey’s test.
A multivariable regression analysis was used to
identify whether the clinical features of depression
were associated with BDNF levels. Regression was
performed in patient groups in which the mean BDNF
level deviated significantly from the control group.
Pearson correlation coefficients between predictors
and BDNF levels were also calculated. Basic covari-
ates were entered in the first step of regression. In the
second step, the clinical features of depression were
entered. The regression model was fit using method
enter. Tolerance of the predictors and normality of
error variances was verified.
To establish whether the use of an antidepressant
effected BDNF levels equally in current and remitted
depression, a 2 (currently depressed versus depression in
(full) remission) 2 (antidepressants; yes or no) ANOVA
was performed. Potential antidepressant-specific associa-
tions between the use of SSRI, tricyclic antidepressant,
serotonin-norepinephrine reuptake inhibitor, NaSSA
and St John’s wort and BDNF levels were evaluated
by contrasting BDNF levels of persons who used one
of these agents against the BDNF level of the anti-
depressant-free persons. Analyses were repeated with
the severity of depressive symptoms and the duration
of antidepressant use as covariates.
Results
Demographics and clinical features
Demographical and clinical features among the five
groups are given in Table 1. ANOVA and w
2 tests
showed that, compared with controls, depressed and
remitted persons were more likely to be female, to be
older, to have received fewer years of education and
to smoke. BMI was higher in current and remitted
antidepressant-treated depressed persons compared
with controls and to antidepressant-free depressed
and remitted persons. The amount of physical activity
was low in the antidepressant treated currently
depressed group relative to the other groups. Post
hoc comparisons on demographical and clinical
features between the current and remitted depressed
groups are given in Table 1.
BDNF levels in persons with current or remitted
depression and controls
An ANOVA model showed a main effect of diagnostic
status on serum levels of BDNF (F1,1578=4.09,
P=0.01). Pairwise comparisons (see Figure 1) indi-
cated that serum BDNF levels were low in anti-
depressant-free depressed patients compared with
controls (d=0.19), to antidepressant-free persons who
were in full remission (d=0.15) and to antidepres-
sant-treated depressed patients (d=0.23). BDNF le-
vels of antidepressant-free persons who were in full
remission and depressed patients who were treated
with an antidepressant were comparable to those of
controls.
BDNF and the clinical features of MDD
The exploration of the association between the
clinical features of MDD and serum BDNF was
restricted to the antidepressant free currently de-
pressed group, as BDNF levels in this group were low
relative to controls.
Pearson’s correlation showed that female gender
and being in the early remission phase of depression
(1–6 months) versus having a current episode were
negatively associated with serum BDNF. Age, BMI,
age at onset of MDD and the presence of comorbid
anxiety were positively associated to serum BDNF
(Table 2).
Basic covariates were entered in the first step of
the multivariable regression analysis, followed by
the clinical features that were entered in step
two. Tolerance of the predictors was high (all>0.70),
indicating that our individual predictors were not
redundant with one another. Error variances were
normally distributed. Results of the first step showed
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BDNF levels. Women had lower levels of BDNF
compared with men (b= 0.10, P=0.02) and older
patients had higher levels of BDNF (b=0.11,
P=0.002) compared with younger patients. Results
of the second step showed that none of the clinical
features (listed in Table 2) was significantly asso-
ciated with serum BDNF. Gender and age preserved
its significance. BMI emerged as a significant (posi-
tive) predictor of serum BDNF. Table 2 presents the
results of the second step of the regression analysis.
BDNF and the use of antidepressants
A 2 (currently depressed versus depression in (full)
remission) 2 (antidepressant use; yes versus no)
ANOVA showed that diagnostic status interacted
with antidepressant use (F1,1578=4.19, P=0.03),
indicating that the use of an antidepressant during a
depressive episode was associated with higher BDNF
levels, whereas in the remission phase, the use of
an antidepressant did not show such an association
Table 1 Demographic and clinical characteristics (percentages (%) or mean±s.d.) of participants by depression diagnosis
















Female (%) 61.0 66.7 67.0 71.1 70.8 <0.05
Age 45.7±12.3 39.8±12.6 42.6±11.0 43.1±12.9 45.4±10.8 <0.001
a,b
Education (years) 13.4±3.3 11.9±3.2 11.7±3.3 12.6±3.1 12.1±3.3 <0.001
BMI 25.4±4.6 25.5±5.4 26.3±5.6 25.3±4.6 26.6±5.6 <0.01
a,b
Mean met-minutes (weeks)
c 3.7±3.0 3.5±3.3 3.2±3.3 3.8±3.1 3.1±2.8 <0.01
b
Smoker (%) 16.5 38.7 46.0 35.5 34.3 <0.001
a
Alcohol dependent (%) 5.4 23.3 20.0 17.0 13.7 <0.001
Depression severity, IDS 5.3±3.5 29.6±12.7 34.5±13.1 16.8±10.3 20.3±10.6 <0.001
a,b
Age of onset of MDD NA 26.1±12.3 27.4±12.6 27.6±12.2 28.2±11.7 0.35
Chronic MDD (%)
d NA 27.5 38.3 11.1 18.7 <0.001
a,b
>1 episode of MDD (%) NA 63.6 58.2 54.6 61.5 <0.05
a
Comorbid anxiety (%)
e NA 42.2 47.7 NA NA <0.05
Suicide ideation (%) NA 22.4 29.3 5.2 6.2 <0.001
a
Antidepressant medication
SSRI (%) NA NA 62.7 NA 65.8 0.27
SNRI (%) NA NA 16.4 NA 13.0 0.06
TCA (%) NA NA 8.1 NA 13.0 0.19
NaSSA (%) NA NA 8.6 NA 2.5 <0.05
St John’s wort (%) NA NA 4.3 NA 5.6 0.32
Duration of use (months) NA NA 7.5±4.9 NA 10.9±3.5 <0.001
Abbreviations: BMI, body mass index; IDS, inventory of depressive symptoms; MDD, major depressive disorder; NaSSA,
noradrenergic and specific serotonergic antidepressant; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI,
selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.
aIndicates a statistically significant difference (at P<0.05) between the antidepressant treated and antidepressant free current
MDD groups.
bIndicates a statistically significant difference (at P<0.05) between the antidepressant treated and antidepressant free
remitted MDD groups.
cMean met-minutes (that is ratio of energy expenditure during activity to energy expenditure at rest) divided by 1000.
dSymptoms were considered chronic if they were present for at least 24 months during the last 5 years.
eIncluded social phobia, panic disorder with and without agoraphobia, agoraphobia and generalized anxiety disorder.
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Controls Current Remitted Current Remitted
Depression status
(n=161) (n=539) (n=541) (n=382) (n=421)
Figure 1 Plotted are mean serum brain-derived neuro-
trophic factor (BDNF) levels by diagnoses and antidepres-
sant use. Error bars reflect the standard error of the mean.
*Denotes statistical significance at P<0.05. **Denotes
statistical significance at P<0.01.
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antidepressant use were not observed.
To uncover potential differences between various
classes of antidepressants, we compared BDNF levels
of depressed patients who used SSRIs, serotonin-
norepinephrine reuptake inhibitors, tricyclic antide-
pressants, NaSSAs or St John’s wort among each other
and with BDNF level of antidepressant-free depressed
patients. This analysis was restricted to the currently
depressed group as the effect of the use of an
antidepressant on serum BDNF levels was confined
to this group. In this group, 67% (n=282) used
antidepressant for longer than 12 weeks. We observed
a main effect of group (F5,941=4.29, P<0.001). Post
hoc comparisons (see Figure 2) showed that, relative
to not using an antidepressant, the use of SSRIs
(d=0.39) and St John’s wort (d=0.63) was associated
with high levels of BDNF. The use of a NaSSA was
associated with low levels of BDNF relative to SSRI
(d=0.54) and St John’s wort (d=0.85) use. Analyses
were run with and without co-varying for the severity
of depressive symptoms and for the duration of
antidepressant use. These analyses revealed a similar
pattern of results. Furthermore, serum BDNF levels
were unrelated to treatment duration (r= 0.02,
P=0.65), which might suggest that our findings were
not driven by the duration of antidepressant use.
Discussion
Largely in accord with previous findings
6,7 and with
the neurotrophin hypothesis of depression,
3,4 our
data showed that serum BDNF levels were low in
antidepressant-free depressed patients compared
with healthy controls. Our data further showed that
BDNF levels were low in depressed patients who
were not on antidepressant medication compared
with antidepressant-free persons who were in full
remission and that BDNF levels of this latter group
were comparable to those of controls. Herewith,
Table 2 Results of correlation and multivariable regression analyses of demographical and clinical characteristics with serum
levels of BDNF in antidepressant free patients with MDD
r
a B 95% CI B b tP -value
Gender (1=male, 2=female)  0.13**  0.65  1.24 to  0.06  0.10  2.15 0.03
Age (continuous, years) 0.17** 0.03 0.01 to 0.06 0.11 1.98 0.04
Education (continuous, years)  0.04  0.01  0.09 to 0.08  0.005  0.11 0.91
BMI (continuous) 0.13** 0.06 0.01 to 0.10 0.09 1.97 0.04
Met-minutes (continuous, IPAQ)  0.02  0.001  0.01 to 0.01  0.009  0.21 0.83
Smoker (1=no, 2=yes)  0.02  0.07  0.04 to 0.02  0.02  0.44 0.66
Time of Blood withdrawal (continuous)
b  0.04  0.004  0.12 to 0.02  0.04  1.11 0.23
Duration of serum storage (continuous, days) 0.02 0.14  0.40 to 0.68 0.02 0.49 0.62
MDD status (1=current, 2=early remitted)
c  0.11*  0.15  0.50 to 0.25  0.04  0.64 0.52
MDD severity (continuous, IDS) 0.03  0.007  0.04 to 0.02  0.06  1.12 0.24
MDD type (1=single episode, 2=recurrent) 0.01 0.05  0.56 to 0.66 0.007 0.15 0.88
Comorbid anxiety disorder (1=no, 2=yes) 0.08* 0.31  0.36 to 0.97 0.05 0.91 0.36
Age at onset MDD (continuous) 0.14** 0.08  0.04 to 0.18 0.07 1.25 0.21
Chronic MDD (1=no, 2=yes) 0.07 0.19  0.49 to 0.87 0.03 0.55 0.58
Suicide ideation (1=no, 2=yes) 0.06 0.59  0.13 to 1.33 0.07 1.51 0.12
Abbreviations: BDNF, brain-derived neurotrophic factor; BMI, body mass index; CI, confidence interval; IDS, inventory of
depressive symptoms; IPAQ, international physical activity questionnaire; MDD, major depressive disorder.
*Denotes statistical significance of the univariate correlation at P<0.05.
**Denotes statistical significance of the univariate correlation at P<0.01.
aUnivariate correlation with serum levels of BDNF; Pearson’s r for continuous variables and Spearman’s r for variables.
bIn minutes from 0600 hours.































SSRIs SNRIs TCAs NaSSAs
(n=17) (n=262) (n=69) (n=34) (n=34)
Figure 2 Plotted are mean serum brain-derived neuro-
trophic factor (BDNF) levels by specific class of antidepres-
sant (St John’s wort, selective serotonin reuptake inhibitors
(SSRIs), serotonin-norepinephrine reuptake inhibitors
(SNRIs), tricyclic antidepressants (TCAs) and noradrenergic
and specific serotonergic antidepressants (NaSSAs)). The
dashed line indicates the mean BDNF level of the anti-
depressant-free depressed group. Error bars reflect the
standard error of the mean. *Denotes statistical significance
at P<0.05. **Denotes statistical significance at P<0.01.
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14 that low levels
of BDNF in serum are a state characteristic for
depression. In line with one study that reported low
levels of BDNF in euthymic patients,
15 we found that
patients who were in early remission (1–6 months)
had serum BDNF levels that were comparable to those
of currently depressed patients. Thus, serum BDNF
levels remain low after clinical improvement has set
in. This could indicate that low levels of BDNF are
a consequence of depressive symptoms that persist
into early remission. Alternatively, the low levels of
BDNF during early remission might also represent
a scar of a depressive episode. These explanations
could not be fully elucidated in the current study
and longitudinal designs clearly are essential to
understand this issue.
We were unable to replicate the earlier findings that
a higher depression severity,
17,35 having a recurrent
compared with a first episode of MDD
16 and the
occurrence of suicide ideation
36,37 are accompanied
by lower levels of BDNF. In fact, we even found that
the early remission phase, which was accompanied
by a lower symptom severity of depression (mean
inventory of depressive symptoms scores were
22.4±11.4 versus 32.4±12.1 in early remitted and
currently depressed patients respectively), was asso-
ciated with somewhat lower BDNF levels compared
with the current depressive state. The other clinical
features (that is age at onset of depression, the
presence of comorbid anxiety and the chronicity of
depression) also were unrelated to serum BDNF in
multivariable analyses. These findings, given the size
of the current cohort, give us confidence in excluding
the clinical features of depression as potential
correlates of serum BDNF levels. This might be an
important conclusion, as it hints that other (than
specifically depression related) factors may be at play
in the relative fall of BDNF levels during a depressive
episode. Interestingly, being male and having a higher
BMI were found to be positively associated with
BDNF among antidepressant-free depressed patients.
Although these findings were unsought, they parallel
the results of some previous studies,
17,38,39 and they
give ground to interesting hypotheses. For example,
as weight loss is a prime behavioral abnormality of
depression
19 and often a residual symptom in early
remission
40,41 it could be that, alternations in BDNF
levels are mediated by (transient) changes in eating
behavior during, or in the aftermath of, a depressive
episode. Likewise, weight gain is a documented side
effect of antidepressant treatment,
42,43 and thus the
absence of weight loss could potentially explain the
absence of a relative fall of BDNF in depressed
patients during treatment with an antidepressant.
Alternative factors that have been proposed to
underlie the low levels of BDNF during depression
are exposure to stressful life events. Two studies, for
example, found that adverse life events are associ-
ated with lower peripheral BDNF levels within a
depressed and bipolar patient samples.
44,45 Therefore,
it seems worthwhile to integrate a wider range of
variables, notably (early) adverse life events, but
also genetic variants and their interactions with
environmental variables
46 in models that study the
link between BDNF and depression.
In addition, we found that serum BDNF levels were
higher in antidepressant-treated patients compared
with patients who were antidepressant free. This
finding largely is in accord with previous findings.
6,7
We were able to expand previous findings by showing
that the use of an antidepressant is associated with
increased serum BDNF during a depressive episode
but not during remission. This suggests that anti-
depressant-induced increases in BDNF occur in a
disease state when BDNF functioning might be
defective and not in remission when BDNF function-
ing is normalized. In addition, we found the increase
in serum BDNF levels to be a specific associate of the
use of SSRIs and St John’s wort and not of the use of
serotonin-norepinephrine reuptake inhibitors, tricyc-
lic antidepressants or NaSSAs. Although not directly
confirmed, this finding might be explained by
increased availability of extra-synaptic levels of
serotonin. It is known that serotonin stimulates the
expression of BDNF.
47,48 In line with this, we found
the highest BDNF levels in patients who were treated
with an agent that generally leads to an increase in the
availability of serotonin (that is SSRIs and St John’s
wort).
49,50 Furthermore, we found the lowest levels
of BDNF in patients who were treated with agents
that have little or no impact on the availability
of serotonin (that is NaSSAs).
43,51 Nevertheless, this
antidepressant-specific finding seems at odds with
the specific prediction of the neurotrophin hypoth-
esis, stating that increases in BDNF levels are a key
mediator for an antidepressant response to occur.
3
According to this prediction, one might expect that
antidepressants that are known to be about equally
efficacious in the treatment of the symptoms of
depression
50–52 would have similar effects on serum
BDNF levels. Yet another finding that seems hard to
reconcile with the neurotrophin hypothesis is that the
group of depressed persons who used antidepressants
(prolonged and frequently) had the highest BDNF
levels, but also the highest symptom severity of
depression. This suggests, to our belief that in-
creases in peripheral BDNF levels do not parallel
clinical effectiveness, or at least have no direct
effects on the depression characteristics such as its
severity. Such a conclusion on the absence of direct
effects could also be drawn on the findings that the
severity of a depressive episode was unrelated to
serum BDNF levels and that persons who were in
early remission had similar levels of BDNF yet
marked lower levels of depression severity compared
with depressed patients.
Caution, however, is warranted when interpreting
our findings on the associations between the use of an
antidepressant and serum levels of BDNF because our
patients were not randomly assigned to the various
drugs (or no drug) conditions. Thus, our findings
might be confounded by indication. An additional
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were collected in a single wave, precluding any form
of causality. Furthermore, we measured serum levels
of BDNF and assume that these measurements mirror
the amount of BDNF in the brain. This assumption
is validated on preclinical work that showed that
cortical and peripheral levels of BDNF are corre-
lated
53–55 but remains complicated, because in addi-
tion to neurons, several other tissues serve as sources
of BDNF in serum.
54 However, various strengths of
our study seem evident and these include the use of
multivariable techniques and the large sample size
(that relates positive to all previous studies and to two
previous meta-analyses
6,7 as well).
In conclusion, we believe that our data indicate that
low levels of BDNF in blood serum are a state
characteristic of depression and thus an abnormality
that is evident during the clinical state and the early
remission phase of depression but not when the
symptoms of depression are in full remission. Our
findings further suggest that some of the core clinical
features of depression are unrelated to serum levels
of BDNF. Finally, increases in serum levels of BDNF
appear to be a specific pharmacological effect of a
subset of antidepressants that does not parallel depres-
sion characteristics such as the severity of depression.
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